Close-up portrait of a man looking into the camera
About us

THERAPEUTIC DERMATOLOGY

The Therapeutic Dermatology market segment encompasses prescription treatments that target moderate to severe skin conditions, from acne to skin cancer.

Galderma has a broad portfolio and a commitment to developing new therapies in diverse disease areas with unmet medical needs. We hold leading positions in acne, rosacea and non-melanoma skin cancer treatments – and nemolizumab is set to enhance our portfolio further. A first-in-class investigational monoclonal antibody, nemolizumab targets the interleukin-31 alpha receptor and has blockbuster potential in both prurigo nodularis (PN) and atopic dermatitis (AD).

 

OUR INJECTABLE AESTHETICS SOLUTIONS

close-up portrait of a middle-aged woman laughing

OUR DERMATOLOGICAL SKINCARE SOLUTIONS

Portrait shot of a black woman laughing

OUR BRANDS

Galderma_Content Images_Our Brands_4.png